Market Overview

Horizon Discovery Presents an Educational Webinar on CRISPR-Cas9 Genome Engineering in Primary T cells

Share:

Through this webinar, which LabRoots will host September 18, attendees will gain a better understanding of the optimal conditions for CRISPR-Cas9 gene editing in primary T cells using RNPs and the rules for designing, synthesizing, and validating efficient guide RNAs.

YORBA LINDA, Calif. (PRWEB) August 21, 2018

CRISPR-Cas9 gene editing strategies have revolutionized our ability to engineer the genomes of diverse cell types and species for the robust functional interrogation of complex biological processes. Gene editing in primary T-cells represents an important research tool for the development of T-cell based immunotherapies, the study of the autoimmunity, the understanding of host-pathogen dynamics that drive HIV replication and latency, and creation of chimeric antigen receptor (CAR) T cells for the treatment of various cancers.

While these cells have proven resistant to traditional transfection and transduction approaches for the CRISPR-Cas9 gene editing, recent advancements in ribonucleoprotein (RNP) delivery have allowed for efficient primary T-cell editing for the first time. In this webinar, we will present a workflow for the design and delivery of CRISPR-Cas9 RNPs to primary, human T-cells by electroporation.

This platform supports the high-throughput, arrayed generation of hundreds of specific gene manipulations in only a few hours' time without the use of recombinant DNA or lentiviruses and without the need for selection markers. This approach is widely adaptable to an array of downstream applications and protocols for the study of diverse T-cell processes.

In this webinar, which is sponsored by Horizon Discovery, participants will learn how this approach is being employed to better understand HIV replication and pathogenesis. They will also learn of best practices and considerations for high-throughput functional screening

The speaker for this event will be Dr. Judd F. Hultquist, an assistant professor of medicine at Northwestern University.

Dr. Hultquist specializes in the adaptation of proteomic and functional genomic technologies to primary models of disease to better understand the molecular dynamics of the host-pathogen relationship. His work on CRISPR technologies with Dr. Nevan Krogan at the University of California, San Francisco, led to the development of the first gene editing platform for primary CD4+ T cells, the identification of several novel pathways that contribute to HIV replication, and the discovery of a new class of CRISPR inhibitors encoded by bacteriophages that maintain their function in mammalian cells.

LabRoots will host this webinar September 18, 2018, beginning at 8 a.m. PDT, 11 a.m. EDT. To learn more about this event, the continuing education credits offered, or to register for free, click here.

About Horizon Discovery Group plc
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalized molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD"

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world's largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

For the original version on PRWeb visit: https://www.prweb.com/releases/horizon_discovery_presents_an_educational_webinar_on_crispr_cas9_genome_engineering_in_primary_t_cells/prweb15707272.htm

View Comments and Join the Discussion!